Insiders who reported open-market trades in the last 12 months at the companies Muthusamy Shanmugam files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Nikhil Lalwani - $5.05M in ANIP purchases and sales in the last 12 months
Patrick D. Walsh - $2.32M in ANIP purchases and sales in the last 12 months
Stephen P. Carey - $1.99M in ANIP purchases and sales in the last 12 months
Christopher Mutz - $1.64M in ANIP purchases and sales in the last 12 months
Chad Gassert - $1.31M in ANIP purchases and sales in the last 12 months
Krista Davis - $785K in ANIP purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Muthusamy Shanmugam is a corporate insider, tracked as HEAD OF R&D, COO-NOVITIUM OPS, Director of ANI PHARMACEUTICALS INC (ANIP). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Muthusamy Shanmugam last file a Form 4?
The most recent primary Form 4 on record is dated 2 March 2026, one of 5 filings going back to 2025.
Has Muthusamy Shanmugam been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($17.91M) across all tracked filings.
Muthusamy Shanmugam is HEAD OF R&D, COO-NOVITIUM OPS, Director of ANI PHARMACEUTICALS INC (ANIP). 5 SEC Form 4 filings on record going back to 2025, most recently on 2 March 2026. Most recent open-market trade: sold $4.79M of ANIP on 20 August 2025. Lifetime open-market sales: $17.91M.
Recent transactions
7
The latest 7 SEC Form 4 transactions reported by Muthusamy Shanmugam.
InsiderAlpha's records for Muthusamy Shanmugam go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
